L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy

L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy

The homing molecule, L-selectin (CD62L), is commonly used as a T cell activation marker, since expression is downregulated following engagement of the T cell receptor. Studies in mice have shown that CD62L+ central memory T cells are better at controlling tumor growth than CD62L− effector memory T c...

Full description

Bibliographic Details
Main Authors: H. Angharad Watson, Ruban R. P. Durairaj, Julia Ohme, Markella Alatsatianos, Hanan Almutairi, Rebar N. Mohammed, Miriam Vigar, Sophie G. Reed, Stephen J. Paisey, Christopher Marshall, Awen Gallimore, Ann Ager
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-06-01
Series:Frontiers in Immunology
Subjects:
L-selectin/CD62L
T cells
melanoma
adoptive T cell therapy
cancer immunotherapy
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.01321/full

Similar Items

Similar Items